The purpose of this study is to evaluate umbilical cord-derived mesenchymal stem cell injectables for the regeneration of partial-thickness rotator cuff tears
Adults aged 19 years or older
Shoulder pain lasting for at least 3 months
A pain visual analogue scale (VAS) score of 4 or greater
Inadequate response to sufficient conservative treatment for at least 3 months, such as medication, injection therapy, physical therapy, or exercise therapy
Receipt of subacromial injection therapy in the affected shoulder within the past 3 months
History of rotator cuff surgery on the affected shoulder within the past 6 months
Previous treatment with a stem cell therapy for the shoulder
Presence of any of the following shoulder conditions: full-thickness rotator cuff tear, obvious isolated acromioclavicular joint arthropathy, or a clear history of trauma to the shoulder joint within the past 3 months
Kyoung Hwan Koh
Lead sponsor
Asan Medical Center
Sponsor institution